This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epigenomics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Noel Doheny

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure13.2yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure4.1yrs

Recent management updates

Recent updates

A Look At The Intrinsic Value Of Epigenomics AG (ETR:ECX1)

Jul 02
A Look At The Intrinsic Value Of Epigenomics AG (ETR:ECX1)

We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn Rate

Jun 12
We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn Rate

When Will Epigenomics AG (ETR:ECX) Breakeven?

Feb 15
When Will Epigenomics AG (ETR:ECX) Breakeven?

CEO

Noel Doheny

13.2yrs

Tenure

Dr. Noel Thomas Doheny has been the Chief Executive Officer of Epigenomics Inc. at Epigenomics AG since May 2011. Dr. Doheny manages all US activities and global business development and partnership develo...


Board Members

NamePositionTenureCompensationOwnership
Helge Lubenow
Chairman of the Supervisory Board8.2yrs€25.00kno data
Alexander Link
Vice-chairman of Supervisory Board4.1yrs€25.00kno data
Jochen Hummel
Member of Supervisory Boardless than a yearno datano data

4.1yrs

Average Tenure

54yo

Average Age

Experienced Board: ECX's board of directors are considered experienced (4.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/10 20:12
End of Day Share Price 2024/07/10 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Epigenomics AG is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hans Bjorn BostromEdison Investment Research
Marietta Miemietzequinet Bank AG (ESN)
Simon ScholesFirst Berlin Equity Research GmbH